Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. - Wikidata - awgldk - TriplyDB

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

http://www.wikidata.org/entity/Q36620016

about

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Small bowel neuroendocrine tumors: From pathophysiology to clinical approach Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review Gastroenteropancreatic high-grade neuroendocrine carcinoma Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology Neuroendocrine tumors of the gastro-entero-pancreatic system Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer.Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Atypical presentation of carcinoid tumor with unresolved right shoulder pain: a case report.Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.Advances in diagnosis and therapy of neuroendocrine tumors.New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Update on the treatment of neuroendocrine tumors.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.Chemotherapy for gastro-enteropancreatic endocrine tumours.Non-transitional cell bladder carcinomas.Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?Poorly Differentiated Neuroendocrine Tumor of the Rectum Coexistent with Giant Rectal Villous Adenoma Presenting as McKittrick-Wheelock Syndrome First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.Poorly differentiated neuroendocrine carcinoma in a perigastric lymph node from an unknown primary site.Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.

P2860

Q24674315-DE507339-6283-4D09-B25E-4B10F847C95E Q24685837-E39B0074-EFA0-4D01-AF0F-315B966689A3 Q26766650-CDA455EE-D448-4C3B-841A-1B57EA52A92F Q26768483-52A57D54-A463-4828-806F-3588D240F4D1 Q26998392-04137168-71CC-45B8-9C24-F5E68F903CB1 Q28078501-4EAF2A73-C3B6-432C-A905-5820075FCE58 Q28294432-E46AD5B6-6501-447B-A441-52B266689B58 Q30238552-55359426-F133-49CD-ACC0-2E43E28F35A6 Q30249051-3483D369-C236-4817-ACB6-ACC76CA4680B Q33388860-DE3852F5-45F2-4B7B-A5A3-96940EBD746E Q33394763-66FF2EE5-82B1-46EE-887C-A5153B787195 Q33648996-D83E42E9-6D85-4DD0-82D3-FF0C934B66AE Q33653772-5C633F4B-D389-4CA0-8AD7-C2438ADC58C2 Q33783119-9706A6BD-E672-4945-8CC1-108F1FD8DCDF Q33957571-99A71ECA-5E63-4E30-B9FF-A6A07A88512A Q34063746-077D54B9-879B-4476-8252-B42821869300 Q34283282-62FC1B89-BF63-4A06-8A9D-A686DD8502AE Q34414279-60FA5962-31CB-4ECA-ABF0-40AAF4DA0417 Q34446086-D9D04428-D757-44C0-954E-149088CAB001 Q34484273-CE2263F9-2CC0-445B-8B58-0D722D83F7FC Q34495609-90D462DD-F893-48BB-9269-61DBE8CE7651 Q34564262-E8BC519C-FA8F-4574-BBFF-99D08ACF4A3D Q34734203-62B5EF09-A736-4D6D-8FF1-19355B642588 Q35097493-F3E709DB-9B4F-4722-BBA9-15BF6321DFC3 Q35178055-F40B8E93-22B7-4F70-84C5-21EF639A8180 Q35371197-3A28E873-E0F0-4650-A889-FF60A8EB1DFD Q35576166-F261FCC9-4007-4A7F-8BE7-E862661491FD Q35669138-73C4B45E-216B-46F4-883C-B0D56B767395 Q35713556-2DE5A041-417D-4FF9-B2AA-5ABEE2FC2799 Q35760798-BB2FEC13-3315-4BEF-AA99-1BF8571E4A5B Q35843079-4C8D8EC2-DC2C-4B18-8436-62557579F945 Q35907055-FDA91424-F71F-4795-9362-A734940B769B Q35915027-0332F08A-B78C-4B3B-8475-78A036184CCD Q36037516-A7EC7A56-6EBD-4FDA-839F-EB2FAA39ECD2 Q36206880-A8E86CA4-E075-4B30-B709-1945DED3B8DA Q36300517-FA0B49A5-9DDB-4F60-8190-9F0C11D06E39 Q36349306-CB970864-316F-4E83-9D64-0087F0D26478 Q36352317-9762373D-8465-46B6-AD86-46BA66F2DDEF Q36537008-218AA495-FCF5-458E-814A-22D30244A5CA Q36610457-468C69FB-9C36-4B9C-A01C-211932F0E3FA

P2860

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

http://www.wikidata.org/entity/Q36620016

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

@ast

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

@en

type

label

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

@ast

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

@en

prefLabel

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

@ast

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

@en

P1433

Q36620016-8B51A351-F4C3-40BB-BFB3-E42744CF4F36

P1476

Q36620016-FF7A9134-AFB6-46E2-822E-5241BE9DB48C

P2093

Q36620016-03B702E5-442E-46CF-B073-8AEA1EE78F7F

Q36620016-0DE29F99-D815-4FFE-9A53-6FC380AB8CDF

Q36620016-1ADAA64D-26B7-4392-9477-E1043D6890DA

Q36620016-42009733-FA68-4364-A7A6-5FC9BDD4B68A

Q36620016-50F8B168-F3BA-4FEF-82FB-1671358565DC

Q36620016-519E47F8-4EB0-4F86-BBFF-D831C2500237

Q36620016-59128513-4059-4184-9E77-33F188D0C2E1

Q36620016-5F3EC5A5-1FF6-4365-B79E-63351DA3B523

Q36620016-6CF692EE-E32A-4941-89DB-BA4296BE439B

Q36620016-DA31962D-4EBD-4C9D-8F00-4D7A715D38A2

P2860

Q36620016-201D0463-EA8A-4AF0-B204-6B67D2C8E42C

Q36620016-298F58FC-E8C3-44D6-96B9-898729824585

Q36620016-2D9C838B-4D8E-4AFA-952C-A8BD0A3BFE7E

Q36620016-45ED545C-BD18-4FBA-B56F-47AFD4DB2F8D

Q36620016-62A4A2B9-AE00-436B-BD0E-0D76C13A522C

Q36620016-7EF7DB5F-639E-49C0-AB9F-B79836022499

Q36620016-9EFE0680-140B-4153-A53A-E6ACABA4EEB6

Q36620016-AA56F6F3-F9B0-4C5E-AF9E-1B25323D8CB2

Q36620016-C5AB9EC6-E86F-4FEC-8442-69B4AB2FBA5E

Q36620016-ED40470C-DBF1-40C0-A3A5-D34081FCBD28

P2888

Q36620016-EFFADB7A-F433-4227-BEDA-01383D456D97

P304

Q36620016-19B02FA6-F2A8-45FB-8146-616E100E3B90

P31

Q36620016-1456F6C4-480B-4E26-9607-C60C6DC57BFD

P356

Q36620016-C3E91CA9-EDE5-4D24-A664-42954A20C741

P407

Q36620016-1436A5F0-AE53-4F4E-8F6C-3BF11F44EDD2

P433

Q36620016-2C58A653-F72E-4B9A-8204-9EC666FC0568

P478

Q36620016-E48BE749-6330-4A8F-B572-D331A032E7D3

P577

Q36620016-D6EEBCFD-39D3-4DA5-9C9B-FBE94CCDEA1D

P5875

Q36620016-6ECA7F7D-5D8E-4986-ADA4-34605BF41C84

P6179

Q36620016-A37E4858-42F4-454F-A200-308EF6C462DB

P698

Q36620016-F28B8F28-B367-4D2B-8878-F37583C7B0A2

P932

Q36620016-D21412F0-66A4-46BF-AADF-B3F16D097A82

P356

P1433

British Journal of Cancer

P1476

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

@en

P2093

Aparicio T

http://www.w3.org/2001/XMLSchema#string

Baudin E

http://www.w3.org/2001/XMLSchema#string

Ducreux M

http://www.w3.org/2001/XMLSchema#string

Duvillard P

http://www.w3.org/2001/XMLSchema#string

Elias D

http://www.w3.org/2001/XMLSchema#string

Lasser P

http://www.w3.org/2001/XMLSchema#string

Mitry E

http://www.w3.org/2001/XMLSchema#string

Rougier P

http://www.w3.org/2001/XMLSchema#string

Rufié P

http://www.w3.org/2001/XMLSchema#string

Sabourin JC

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical aspects of the analysis of data from retrospective studies of disease

Reporting results of cancer treatment

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

An analysis of 8305 cases of carcinoid tumors.

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.

Neuroendocrine neoplasms of the lung. A clinicopathologic update.

Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors.

Neuroendocrine cells and neuroendocrine neoplasms of the lung.

Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.

Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract.

P2888

P304

1351-1355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6690325

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12696208

http://www.w3.org/2001/XMLSchema#string

P6179

1033288252

http://www.w3.org/2001/XMLSchema#string

P698

10604732

http://www.w3.org/2001/XMLSchema#string

P932

2362979

http://www.w3.org/2001/XMLSchema#string